{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:01:50Z","timestamp":1788184910571,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>For patients with locally advanced esophageal squamous cell carcinoma (ESCC) who achieve a clinical complete response (cCR) after comprehensive treatment, organ preservation and observation-waiting strategies provide a more conservative treatment option that enhances the patient\u2019s quality of life. The high cCR rate of chemoradiotherapy combined with immunotherapy is driving the shift in ESCC treatment from traditional radical surgery to organ preservation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>We report a case of a 57-year-old male patient diagnosed with esophageal ESCC who underwent combined radiotherapy, chemotherapy, and immunotherapy. After treatment, the patient achieved a cCR, resulting in 15 months of progression-free survival. At this stage, the primary lesion showed no signs of local regrowth or recurrence; however, unexpected metastasis to the small intestine occurred, leading to bowel obstruction. The metastasis at this occult site was not detected by sensitive monitoring methods, and the side effects of the immunotherapy drugs further complicated the diagnosis and differential diagnosis. The tumor metastasis at the unexpected site was not identified early, but following rescue surgery, the patient survived for an additional 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Organ-preserving surgery for esophageal cancer significantly improves patients\u2019 short-term quality of life. However, owing to incomplete monitoring measures, a cautious approach should be maintained when implementing organ-preserving surgery at this stage. For patients undergoing organ-preserving surgery, continuous active monitoring is essential. Timely intervention should be provided when clinical symptoms arise, and personalized treatment plans should be developed, while remaining vigilant for metastasis at unexpected sites.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1560011","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:53Z","timestamp":1753330253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Small bowel metastasis during organ preservation in patients with esophageal squamous cell carcinoma: case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Qinxing","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbo","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(97)00088-9","article-title":"Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer","volume":"33","author":"Bleiberg","year":"1997","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.3765","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901","volume":"32","author":"Mariette","year":"2014","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.450","article-title":"Deciphering radiological stable disease to immune checkpoint inhibitors","volume":"33","author":"Luo","year":"2022","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/jco.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S1317","DOI":"10.1016\/j.annonc.2023.10.076","article-title":"LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial","volume":"34","author":"van der Wilk","year":"2023","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.935374","article-title":"Conversion surgery following immunochemotherapy in initially unresectable locally advanced esophageal squamous cell carcinoma-A real-world multicenter study (RICE-retro)","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1236","article-title":"Chemoradiotherapy and subsequent immunochemotherapy as conversion therapy in unresectable locally advanced esophageal squamous cell carcinoma: A phase II NEXUS-1 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-16955-0","article-title":"Conversion from radical esophagectomy to definitive chemoradiotherapy after neoadjuvant chemotherapy for advanced esophageal squamous cell carcinoma: treatment options based on chemotherapy response","volume":"32","author":"Narita","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524801","article-title":"Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study","volume":"19","author":"Noordman","year":"2018","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12885-020-6669-y","article-title":"Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1657310","DOI":"10.1155\/2017\/1657310","article-title":"Esophageal cancer metastases to unexpected sites: A systematic review","volume":"2017","author":"Shaheen","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/joa.12552","article-title":"The peri-esophageal connective tissue layers and related compartments: visualization by histology and magnetic resonance imaging","volume":"230","author":"Weijs","year":"2017","journal-title":"J Anat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/00000658-199409000-00012","article-title":"Radical lymph node dissection for cancer of the thoracic esophagus","volume":"220","author":"Akiyama","year":"1994","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/12500248","article-title":"A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy","volume":"85","author":"Ding","year":"2012","journal-title":"Br J Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.029","article-title":"Arterial or venous: where are the circulating tumor cells","volume":"2","author":"Gray","year":"2015","journal-title":"EBioMedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0234-2","article-title":"Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis","volume":"16","author":"Koh","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","article-title":"Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: A comparative study using the peritoneal surface disease severity score (PSDSS)","volume":"27","author":"Baratti","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3322\/caac.21749","article-title":"The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future","volume":"73","author":"Foster","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s2589-7500(22)00040-1","article-title":"Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study","volume":"4","author":"Jiang","year":"2022","journal-title":"Lancet Digit Health"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000004229","article-title":"Development and validation of an image-based deep learning algorithm for detection of synchronous peritoneal carcinomatosis in colorectal cancer","volume":"275","author":"Yuan","year":"2022","journal-title":"Ann Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(73)91228-2","article-title":"Why are small-bowel tumours so rare","volume":"1","author":"Lowenfels","year":"1973","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9728424","DOI":"10.1155\/2021\/9728424","article-title":"Small bowel obstruction caused by small intestinal metastasis secondary to esophageal carcinoma","volume":"2021","author":"Naoshima","year":"2021","journal-title":"Case Rep Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","article-title":"Gastrointestinal and hepatic complications of immune checkpoint inhibitors","volume":"19","author":"Cramer","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217738325","article-title":"Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient","volume":"25","author":"Fragulidis","year":"2019","journal-title":"J Oncol Pharm Pract"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1560011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T04:10:54Z","timestamp":1753330254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1560011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1560011"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1560011","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1560011"}}